Missing link between microRNA and prostate cancer

Tumor Biology

Volumn 37, Issue 5, 2016, Pages 5683-5704

  Gill, Balraj Singh ^a   Alex, Jimi Marin ^a   Navgeet, ^a   Kumar, Sanjeev ^a  

^a CENTRAL UNIVERSITY OF PUNJAB   (India)

Author keywords

Apoptosis; Biomarker; miRNA; Prostate cancer (PCa); Signaling

Indexed keywords

CETUXIMAB; MICRORNA; MICRORNA 1; MICRORNA 101; MICRORNA 133; MICRORNA 141; MICRORNA 143; MICRORNA 145; MICRORNA 146A; MICRORNA 15A 16; MICRORNA 185; MICRORNA 188 5P; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; MICRORNA 205; MICRORNA 208; MICRORNA 218; MICRORNA 222; MICRORNA 296; MICRORNA 29B; MICRORNA 31; MICRORNA 330; MICRORNA 331 3P; MICRORNA 342; MICRORNA 34A; MICRORNA 34B; MICRORNA 34C; MICRORNA 449A; UNCLASSIFIED DRUG; UNINDEXED DRUG; ANDROGEN; RNA; SIGNAL PEPTIDE; TUMOR PROTEIN;

APOPTOSIS; CARCINOGENESIS; CELL CYCLE; DIETARY INTAKE; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; GENE EXPRESSION; GENE FUNCTION; GENE TARGETING; GENETIC LINKAGE; HUMAN; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; UPREGULATION; ADENOCARCINOMA; CELL MOTION; GENE EXPRESSION REGULATION; GENETICS; MALE; METABOLISM; NEOPLASM; PATHOLOGY; PHYSIOLOGY; PROSTATE TUMOR; TUMOR INVASION;

ADENOCARCINOMA; ANDROGENS; APOPTOSIS; CELL MOVEMENT; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM PROTEINS; NEOPLASMS, HORMONE-DEPENDENT; PROSTATIC NEOPLASMS; RNA, NEOPLASM; SIGNAL TRANSDUCTION;

EID: 84955614581     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-016-4900-x     Document Type: Review

References (196)

1. Croce CM. Oncogenes and cancer. N Engl J Med. 2008;358(5):502–11.
2. Anand SS, Gill BS. Breakthroughs in epigenetics. PharmaTutor. 2015;3(7):16–24.
3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
4. Kuhn DE, Martin MM, Feldman DS, Terry AV, Nuovo GJ, Elton TS. Experimental validation of miRNA targets. Methods. 2008;44(1):47–54.
5. Maziere P, Enright AJ. Prediction of microRNA targets. Drug Discov Today. 2007;12(11):452–8.
6. Coppola V, De Maria R, Bonci D. MicroRNAs and prostate cancer. Endocr Relat Cancer. 2010;17(1):F1–F17.
7. Bartels CL, Tsongalis GJ. MicroRNAs: novel biomarkers for human cancer. Clin Chem. 2009;55(4):623–31.
8. Wang Q, Li W, Zhang Y, Yuan X, Xu K, Yu J, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell. 2009;138(2):245–56.
9. Denmeade SR, Isaacs JT. A history of prostate cancer treatment. Nat Rev Cancer. 2002;2(5):389–96.
10. Mitchell PS, Parkin RK, Kroh EM, Fritz BR, Wyman SK, Pogosova-Agadjanyan EL, et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci. 2008;105(30):10513–8.
11. Friedman RC, Farh KK-H, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res. 2009;19(1):92–105.
12. Stark A, Brennecke J, Bushati N, Russell RB, Cohen SM. Animal MicroRNAs confer robustness to gene expression and have a significant impact on 3′ UTR evolution. Cell. 2005;123(6):1133–46.
13. Olsen PH, Ambros V. The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. Dev Biol. 1999;216(2):671–80.
14. Catto JW, Alcaraz A, Bjartell AS, De Vere White R, Evans CP, Fussel S, et al. MicroRNA in prostate, bladder, and kidney cancer: a systematic review. Eur Urol. 2011;59(5):671–81.
15. Cortez MA, Bueso-Ramos C, Ferdin J, Lopez-Berestein G, Sood AK, Calin GA. MicroRNAs in body fluids—the mix of hormones and biomarkers. Nat Rev Clin Oncol. 2011;8(8):467–77.
16. Sita-Lumsden A, Dart DA, Waxman J, Bevan C. Circulating microRNAs as potential new biomarkers for prostate cancer. Br J Cancer. 2013;108(10):1925–30.
17. Iguchi H, Kosaka N, Ochiya T. Secretory microRNAs as a versatile communication tool. Commun Integr Biol. 2010;3(5):478–81.
18. Sekeres MA, Peterson B, Dodge RK, Mayer RJ, Moore JO, Lee EJ, et al. Differences in prognostic factors and outcomes in African Americans and whites with acute myeloid leukemia. Blood. 2004;103(11):4036–42.
19. Zovoilis A, Agbemenyah HY, Agis‐Balboa RC, Stilling RM, Edbauer D, Rao P, et al. microRNA‐34c is a novel target to treat dementias. EMBO J. 2011;30(20):4299–308.
20. Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer’s disease hippocampus. Neuroreport. 2007;18(3):297–300.
21. Hébert SS, Horré K, Nicolaï L, Papadopoulou AS, Mandemakers W, Silahtaroglu AN, et al. Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer’s disease correlates with increased BACE1/β-secretase expression. Proc Natl Acad Sci. 2008;105(17):6415–20.
22. Miñones-Moyano E, Porta S, Escaramís G, Rabionet R, Iraola S, Kagerbauer B, et al. MicroRNA profiling of Parkinson’s disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function. Hum Mol Genet. 2011;20(15):3067–78.
23. Schröder FH, Roobol MJ. Defining the optimal prostate-specific antigen threshold for the diagnosis of prostate cancer. Curr Opin Urol. 2009;19(3):227–31.
24. Calin GA, Dumitru CD, Shimizu M, Bichi R, Zupo S, Noch E, et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci. 2002;99(24):15524–9.
25. Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007;67(13):6130–5.
26. Wei J-J, Wu X, Peng Y, Shi G, Olca B, Yang X, et al. Regulation of HMGA1 expression by microRNA-296 affects prostate cancer growth and invasion. Clin Cancer Res. 2011;17(6):1297–305.
27. Hudson RS, Yi M, Esposito D, Watkins SK, Hurwitz AA, Yfantis HG, et al. MicroRNA-1 is a candidate tumor suppressor and prognostic marker in human prostate cancer. Nucleic Acids Res. 2011:gkr1222.
28. Xu L, Zhang Y, Wang H, Zhang G, Ding Y, Zhao L. Tumor suppressor miR-1 restrains epithelial-mesenchymal transition and metastasis of colorectal carcinoma via the MAPK and PI3K/AKT pathway. J Transl Med. 2014;12(1):244.
29. Gaur S, Gallick G. Tumor suppressive miRNA-145 inhibits IGF-1 and cell viability in prostate cancer cells. Cancer Res. 2014;74(19 Supplement):4356.
30. Lee K-H, Chen Y-L, Yeh S, Hsiao M, Lin J, Goan Y, et al. MicroRNA-330 acts as tumor suppressor and induces apoptosis of prostate cancer cells through E2F1-mediated suppression of Akt phosphorylation. Oncogene. 2009;28(38):3360–70.
31. Xu B, Wang N, Wang X, Tong N, Shao N, Tao J, et al. MiR‐146a suppresses tumor growth and progression by targeting EGFR pathway and in ap‐ERK‐dependent manner in castration‐resistant prostate cancer. Prostate. 2012;72(11):1171–8.
32. Jurkin J, Schichl YM, Koeffel R, Bauer T, Richter S, Konradi S, et al. miR-146a is differentially expressed by myeloid dendritic cell subsets and desensitizes cells to TLR2-dependent activation. J Immunol. 2010;184(9):4955–65.
33. Varambally S, Cao Q, Mani R-S, Shankar S, Wang X, Ateeq B, et al. Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer. Science. 2008;322(5908):1695–9.
34. Bonci D, Coppola V, Musumeci M, Addario A, Giuffrida R, Memeo L, et al. The miR-15a–miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med. 2008;14(11):1271–7.
35. Voulgari A, Pintzas A. Epithelial–mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. BBA Rev Cancer. 2009;1796(2):75–90.
36. Fuse M, Nohata N, Kojima S, Sakamoto S, Chiyomaru T, Kawakami K, et al. Restoration of miR-145 expression suppresses cell proliferation, migration and invasion in prostate cancer by targeting FSCN1. Int J Oncol. 2011;38(4):1093.
37. Gandellini P, Giannoni E, Casamichele A, Taddei ML, Callari M, Valdagni R, et al. MiR-205 puts the brakes on the malignant interplay between prostate cancer cells and associated fibroblasts. Cancer Res. 2013;73(3 Supplement):B18-B.
38. Epis MR, Giles KM, Barker A, Kendrick TS, Leedman PJ. miR-331-3p regulates ERBB-2 expression and androgen receptor signaling in prostate cancer. J Biol Chem. 2009;284(37):24696–704.
39. Noonan E, Place R, Pookot D, Basak S, Whitson J, Hirata H, et al. miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene. 2009;28(14):1714–24.
40. Noonan EJ, Place RF, Basak S, Pookot D, Li L-C. miR-449a causes Rb-dependent cell cycle arrest and senescence in prostate cancer cells. Oncotarget. 2010;1(5):349.
41. Han G, Fan M, Zhang X. microRNA-218 inhibits prostate cancer cell growth and promotes apoptosis by repressing TPD52 expression. Biochem Biophys Res Commun. 2015;456(3):804–9. doi:10.1016/j.bbrc.2014.12.026.
42. Zhang H, Qi S, Zhang T, Wang A, Liu R, Guo J, et al. miR-188-5p inhibits tumour growth and metastasis in prostate cancer by repressing LAPTM4B expression. Oncotarget. 2015;6(8):6092–104.
43. Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nohata N, et al. Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer. 2012;106(2):405–13.
44. Ru P, Steele R, Newhall P, Phillips NJ, Toth K, Ray RB. miRNA-29b suppresses prostate cancer metastasis by regulating epithelial–mesenchymal transition signaling. Mol Cancer Ther. 2012;11(5):1166–73.
45. Steele R, Mott JL, Ray RB. MBP-1 upregulates miR-29b, which represses Mcl-1, collagens, and matrix metalloproteinase-2 in prostate cancer cells. Genes Cancer. 2010;1(4):381–7.
46. Liang J, Li Y, Daniels G, Sfanos K, De Marzo A, Wei J, et al. LEF1 targeting EMT in prostate cancer invasion is regulated by miR-34a. Mol Cancer Res. 2015. doi:10.1158/1541-7786.mcr-14-0503.
47. Li X, Chen Y-T, Josson S, Mukhopadhyay NK, Kim J, Freeman MR, et al. MicroRNA-185 and 342 inhibit tumorigenicity and induce apoptosis through blockade of the SREBP metabolic pathway in prostate cancer cells. PLoS One. 2013;8(8):e70987.
48. Zhang Q. Epigenetic regulation of miR-31 and miR-205 of apoptosis in prostate cancer. Cancer Res. 2014;74(19 Supplement):3535.
49. Nadiminty N, Tummala R, Lou W, Zhu Y, Zhang J, Chen X, et al. MicroRNA let-7c suppresses androgen receptor expression and activity via regulation of Myc expression in prostate cancer cells. J Biol Chem. 2012;287(2):1527–37.
50. Zhang Y, Fan K-J, Sun Q, Chen A-Z, Shen W-L, Zhao Z-H, et al. Functional screening for miRNAs targeting Smad4 identified miR-199a as a negative regulator of TGF-β signalling pathway. Nucleic Acids Res. 2012;40(18):9286–97.
51. Zhang J, Zhang D, Wu G-Q, Feng Z-Y, Zhu S-M. Propofol inhibits the adhesion of hepatocellular carcinoma cells by upregulating microRNA-199a and downregulating MMP-9 expression. Hepatobiliary Pancreat Dis Int. 2013;12(3):305–9.
52. Maugeri-Saccà M, Coppola V, Bonci D, De Maria R. MicroRNAs and prostate cancer: from preclinical research to translational oncology. Cancer J. 2012;18(3):253–61.
53. Vandewalle C, Comijn J, De Craene B, Vermassen P, Bruyneel E, Andersen H, et al. SIP1/ZEB2 induces EMT by repressing genes of different epithelial cell–cell junctions. Nucleic Acids Res. 2005;33(20):6566–78.
54. Ding X, Park SI, McCauley LK, Wang C-Y. Signaling between transforming growth factor β (TGF-β) and transcription factor SNAI2 represses expression of microRNA miR-203 to promote epithelial-mesenchymal transition and tumor metastasis. J Biol Chem. 2013;288(15):10241–53.
55. Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, et al. The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol. 2008;10(5):593–601.
56. Rajendiran B. Post-transcriptional and epigenetic regulation of MIEN1 in prostate cancer. 2014.
57. Formosa A, Lena A, Markert E, Cortelli S, Miano R, Mauriello A, et al. DNA methylation silences miR-132 in prostate cancer. Oncogene. 2013;32(1):127–34.
58. Liu H, Yin J, Wang H, Jiang G, Deng M, Zhang G, et al. FOXO3a modulates WNT/β-catenin signaling and suppresses epithelial-to-mesenchymal transition in prostate cancer cells. Cell Signal. 2015;27(3):510–18.
59. Guo Y, Ying L, Tian Y, Yang P, Zhu Y, Wang Z, et al. miR‐144 downregulation increases bladder cancer cell proliferation by targeting EZH2 and regulating Wnt signaling. FEBS J. 2013;280(18):4531–8.
60. Zhang L-Y, Lee VH-F, Wong AMG, Kwong DL-W, Zhu Y-H, Dong S-S, et al. MicroRNA-144 promotes cell proliferation, migration and invasion in nasopharyngeal carcinoma through repression of PTEN. Carcinogenesis.
61. Zha W, Cao L, Shen Y, Huang M. Roles of Mir-144-ZFX pathway in growth regulation of non-small-cell lung cancer. PLoS One. 2013;8(9):e74175.
62. Lal A, Pan Y, Navarro F, Dykxhoorn DM, Moreau L, Meire E, et al. miR-24–mediated downregulation of H2AX suppresses DNA repair in terminally differentiated blood cells. Nat Struct Mol Biol. 2009;16(5):492–8.
63. Hu H, Du L, Nagabayashi G, Seeger RC, Gatti RA. ATM is down-regulated by N-Myc–regulated microRNA-421. Proc Natl Acad Sci. 2010;107(4):1506–11.
64. Grosso S, Doyen J, Parks S, Bertero T, Paye A, Cardinaud B, et al. MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis. 2013;4(3):e544.
65. Jin M, Zhang T, Liu C. MicroRNA-128 suppresses prostate cancer by inhibiting BMI-1. Cancer Res. 2014;74(15):4183–95.
66. Xue G, Ren Z, Chen Y, Zhu J, Du Y, Pan D, et al. A feedback regulation between miR-145 and DNA methyltransferase 3b in prostate cancer cell and their responses to irradiation. Cancer Lett. 2015. doi:10.1016/j.canlet.2015.02.046.
67. Li T, Li D, Sha J, Sun P, Huang Y. MicroRNA-21 directly targets MARCKS and promotes apoptosis resistance and invasion in prostate cancer cells. Biochem Biophys Res Commun. 2009;383(3):280–5.
68. Liu L-Z, Li C, Chen Q, Jing Y, Carpenter R, Jiang Y, et al. MiR-21 induced angiogenesis through AKT and ERK activation and HIF-1α expression. PLoS One. 2011;6(4):e19139.
69. Amir S, Ma A-H, Shi X-B, Xue L, Kung H-J, de Vere White RW. Oncomir miR-125b suppresses p14ARF to modulate p53-dependent and p53-independent apoptosis in prostate cancer. PLoS One. 2013;8(4):e61064.
70. Scaravilli M, Porkka KP, Brofeldt A, Annala M, Tammela TL, Jenster GW, et al. MiR-1247-5p is overexpressed in castration resistant prostate cancer and targets MYCBP2. Prostate. 2015. doi:10.1002/pros.22961.
71. Wang C, Tao W, Ni S, Chen Q, Zhao Z, Ma L, et al. Tumor-suppressive microRNA-145 induces growth arrest by targeting SENP1 in human prostate cancer cells. Cancer Sci. 2015. doi:10.1111/cas.12626.
72. Sylvestre Y, De Guire V, Querido E, Mukhopadhyay UK, Bourdeau V, Major F, et al. An E2F/miR-20a autoregulatory feedback loop. J Biol Chem. 2007;282(4):2135–43.
73. Qin W, Shi Y, Zhao B, Yao C, Jin L, Ma J, et al. miR-24 regulates apoptosis by targeting the open reading frame (ORF) region of FAF1 in cancer cells. PLoS One. 2010;5(2):e9429.
74. Jalava S, Urbanucci A, Latonen L, Waltering K, Sahu B, Jänne O, et al. Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer. Oncogene. 2012;31(41):4460–71.
75. Emmrich S, Rasche M, Schöning J, Reimer C, Keihani S, Maroz A, et al. miR-99a/100∼125b tricistrons regulate hematopoietic stem and progenitor cell homeostasis by shifting the balance between TGFβ and Wnt signaling. Genes Dev. 2014;28(8):858–74.
76. Ishteiwy RA, Ward TM, Dykxhoorn DM, Burnstein KL. The microRNA-23b/-27b cluster suppresses the metastatic phenotype of castration-resistant prostate cancer cells. PLoS One. 2012;7(12):e52106.
77. Aghaee-Bakhtiari SH, Arefian E, Naderi M, Noorbakhsh F, Nodouzi V, Asgari M, et al. MAPK and JAK/STAT pathways targeted by miR-23a and miR-23b in prostate cancer: computational and in vitro approaches. Tumor Biol. 2015;36(6):4203–12.
78. Wu Z, He B, He J, Mao X. Upregulation of miR‐153 promotes cell proliferation via downregulation of the PTEN tumor suppressor gene in human prostate cancer. Prostate. 2013;73(6):596–604.
79. Xu J, Liao X, Wong C. Downregulations of B‐cell lymphoma 2 and myeloid cell leukemia sequence 1 by microRNA 153 induce apoptosis in a glioblastoma cell line DBTRG‐05MG. Int J Cancer. 2010;126(4):1029–35.
80. Wei Y, Yang J, Yi L, Wang Y, Dong Z, Liu Z, et al. MiR-223-3p targeting SEPT6 promotes the biological behavior of prostate cancer. Sci Rep. 2014;4:7546. doi:10.1038/srep07546.
81. Biunno I, Cattaneo M, Orlandi R, Canton C, Biagiotti L, Ferrero S, et al. SEL1L a multifaceted protein playing a role in tumor progression. J Cell Physiol. 2006;208(1):23–38.
82. Bader AG. miR-34—a microRNA replacement therapy is headed to the clinic. Front Genet. 2012;3:120.
83. Gebert LF, Rebhan MA, Crivelli SE, Denzler R, Stoffel M, Hall J. Miravirsen (SPC3649) can inhibit the biogenesis of miR-122. Nucleic Acids Res. 2014;42(1):609–21.
84. Leite KR, Reis ST, Viana N, Morais DR, Moura CM, Silva IA, et al. Controlling RECK miR21 promotes tumor cell invasion and is related to biochemical recurrence in prostate cancer. J Cancer. 2015;6(3):292–301.
85. Majid S, Dar AA, Saini S, Arora S, Shahryari V, Zaman MS, et al. miR-23b represses proto-oncogene Src kinase and functions as methylation-silenced tumor suppressor with diagnostic and prognostic significance in prostate cancer. Cancer Res. 2012;72(24):6435–46.
86. Anand SS, Gill BS. Breakthroughs in epigenetics. PharmaTutor. 2015;3(7):16–24.
87. Ngo TH, Barnard RJ, Cohen P, Freedland S, Tran C, Elshimali YI, et al. Effect of isocaloric low-fat diet on human LAPC-4 prostate cancer xenografts in severe combined immunodeficient mice and the insulin-like growth factor axis. Clin Cancer Res. 2003;9(7):2734–43.
88. Sonn GA, Aronson W, Litwin M. Impact of diet on prostate cancer: a review. Prostate Cancer Prostatic Dis. 2005;8(4):304–10.
89. Stegeman S, Amankwah E, Klein K, O’Mara TA, Kim D, Lin HY, et al. A large scale analysis of genetic variants within putative miRNA binding sites in prostate cancer. Cancer Discov. 2015. doi:10.1158/2159-8290.cd-14-1057.
90. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–8.
91. Brase JC, Johannes M, Schlomm T, Fälth M, Haese A, Steuber T, et al. Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer. 2011;128(3):608–16.
92. Bian X, Shen Y, Zhang G, Gu C, Cai Y, Wang C, et al. Expression of dicer and its related miRNAs in the progression of prostate cancer. PLoS One. 2015;10(3):e0120159. doi:10.1371/journal.pone.0120159.
93. Shi X-B, Xue L, Yang J, Ma A-H, Zhao J, Xu M, et al. An androgen-regulated miRNA suppresses Bak1 expression and induces androgen-independent growth of prostate cancer cells. Proc Natl Acad Sci. 2007;104(50):19983–8.
94. Ma S, Chan YP, Kwan PS, Lee TK, Yan M, Tang KH, et al. MicroRNA-616 induces androgen-independent growth of prostate cancer cells by suppressing expression of tissue factor pathway inhibitor TFPI-2. Cancer Res. 2011;71(2):583–92.
95. Sun T, Yang M, Chen S, Balk S, Pomerantz M, Hsieh CL, et al. The altered expression of MiR‐221/‐222 and MiR‐23b/‐27b is associated with the development of human castration resistant prostate cancer. Prostate. 2012;72(10):1093–103.
96. Mo W, Zhang J, Li X, Meng D, Gao Y, Yang S, et al. Identification of novel AR-targeted microRNAs mediating androgen signalling through critical pathways to regulate cell viability in prostate cancer. PLoS One. 2013;8(2):e56592.
97. McCabe MT, Brandes JC, Vertino PM. Cancer DNA methylation: molecular mechanisms and clinical implications. Clin Cancer Res. 2009;15(12):3927–37.
98. Lujambio A. CpG island hypermethylation of tumor suppressor microRNAs in human cancer. Cell Cycle. 2007;6(12):1454–8.
99. Vrba L, Jensen TJ, Garbe JC, Heimark RL, Cress AE, Dickinson S, et al. Role for DNA methylation in the regulation of miR-200c and miR-141 expression in normal and cancer cells. PLoS One. 2010;5(1):e8697.
100. Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, et al. Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Res. 2008;68(11):4123–32.
101. Suh SO, Chen Y, Zaman MS, Hirata H, Yamamura S, Shahryari V, et al. MicroRNA-145 is regulated by DNA methylation and p53 gene mutation in prostate cancer. Carcinogenesis. 2011;32(5):772–8.
102. Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci. 2009;106(9):3207–12.
103. Gu W, Gao T, Shen J, Sun Y, Zheng X, Wang J, et al. MicroRNA-183 inhibits apoptosis and promotes proliferation and invasion of gastric cancer cells by targeting PDCD4. Int J Clin Exp Med. 2014;7(9):2519.
104. Meng F, Henson R, Wehbe-Janek H, Ghoshal K, Jacob ST, Patel T. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology. 2007;133(2):647–58.
105. Gill BS, Sharma P, Kumar R, Kumar S. Misconstrued versatility of Ganoderma lucidum: a key player in multi-targeted cellular signaling. Tumor Biol. 2015. p. 1–16.
106. Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci. 2005;102(39):13944–9.
107. Porkka KP, Ogg EL, Saramäki OR, Vessella RL, Pukkila H, Lähdesmäki H, et al. The miR‐15a‐miR‐16‐1 locus is homozygously deleted in a subset of prostate cancers. Genes Chromosomes Cancer. 2011;50(7):499–509.
108. Se C, Tian J, Chen S, Zhang X, Zhang Y. Role of miR‐34c in ketamine‐induced neurotoxicity in neonatal mice hippocampus. Cell Biol Int. 2015;39(2):164–8.
109. Gong J, Zhang J, Li B, Zeng C, You K, Chen M, et al. MicroRNA-125b promotes apoptosis by regulating the expression of Mcl-1, Bcl-w and IL-6R. Oncogene. 2013;32(25):3071–9.
110. Hersh EM, Metch BS, Muggia FM, Brown TD, Whitehead RP, Budd GT, et al. Phase II studies of recombinant human tumor necrosis factor alpha in patients with malignant disease: a summary of the Southwest Oncology Group experience. J Immunother. 1991;10(6):426–31.
111. Garofalo M, Quintavalle C, Di Leva G, Zanca C, Romano G, Taccioli C, et al. MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer. Oncogene. 2008;27(27):3845–55.
112. Ovcharenko D, Kelnar K, Johnson C, Leng N, Brown D. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. Cancer Res. 2007;67(22):10782–8.
113. Yamamura S, Saini S, Majid S, Hirata H, Ueno K, Deng G, et al. MicroRNA-34a modulates c-Myc transcriptional complexes to suppress malignancy in human prostate cancer cells. PLoS One. 2012;7(1):e29722.
114. Li X, Pan J-H, Song B, Xiong E-Q, Chen Z-W, Zhou Z-S, et al. Suppression of CX43 expression by miR-20a in the progression of human prostate cancer. Cancer Biol Ther. 2012;13(10):890–8.
115. Williams SA, Singh P, Isaacs JT, Denmeade SR. Does PSA play a role as a promoting agent during the initiation and/or progression of prostate cancer? Prostate. 2007;67(3):312–29.
116. Saini S, Majid S, Yamamura S, Tabatabai L, Suh SO, Shahryari V, et al. Regulatory role of miR-203 in prostate cancer progression and metastasis. Clin Cancer Res. 2011;17(16):5287–98.
117. Davis JN, Wojno KJ, Daignault S, Hofer MD, Kuefer R, Rubin MA, et al. Elevated E2F1 inhibits transcription of the androgen receptor in metastatic hormone-resistant prostate cancer. Cancer Res. 2006;66(24):11897–906.
118. Gill BS, Kumar S. Differential algorithms-assisted molecular modeling-based identification of mechanistic binding of ganoderic acids. Med Chem Res. 2015;24(9):3483–93.
119. Christoffersen NR, Silahtaroglu A, Ørom UA, Kauppinen S, Lund AH. miR-200b mediates post-transcriptional repression of ZFHX1B. RNA. 2007;13(8):1172–8.
120. Karolina DS, Armugam A, Tavintharan S, Wong MT, Lim SC, Sum CF, et al. MicroRNA 144 impairs insulin signaling by inhibiting the expression of insulin receptor substrate 1 in type 2 diabetes mellitus. PLoS One. 2011;6(8):e22839.
121. Qi W, Chan H, Teng L, Li L, Chuai S, Zhang R, et al. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation. Proc Natl Acad Sci. 2012;109(52):21360–5.
122. Davis BN, Hilyard AC, Lagna G, Hata A. SMAD proteins control DROSHA-mediated microRNA maturation. Nature. 2008;454(7200):56–61.
123. Connolly EC, Freimuth J, Akhurst RJ. Complexities of TGF-β targeted cancer therapy. Int J Biol Sci. 2012;8(7):964–78. doi:10.7150/ijbs.4564.
124. Heldin C-H, Moustakas A. Role of Smads in TGFβ signaling. Cell Tissue Res. 2012;347(1):21–36.
125. Fleming NI, Jorissen RN, Mouradov D, Christie M, Sakthianandeswaren A, Palmieri M, et al. SMAD2, SMAD3 and SMAD4 mutations in colorectal cancer. Cancer Res. 2013;73(2):725–35.
126. Kim S-J, Im Y-H, Markowitz S, Bang Y-J. Molecular mechanisms of inactivation of TGF-β receptors during carcinogenesis. Cytokine Growth Factor Rev. 2000;11(1):159–68.
127. Wikström P, Damber JE, Bergh A. Role of transforming growth factor‐β1 in prostate cancer. Microsc Res Tech. 2001;52(4):411–9.
128. Davis-Dusenbery BN, Chan MC, Reno KE, Weisman AS, Layne MD, Lagna G, et al. Down-regulation of Krüppel-like Factor-4 (KLF4) by microRNA-143/145 is critical for modulation of vascular smooth muscle cell phenotype by transforming growth factor-β and bone morphogenetic protein 4. J Biol Chem. 2011;286(32):28097–110.
129. Zhang H, Cai X, Wang Y, Tang H, Tong D, Ji F. microRNA-143, down-regulated in osteosarcoma, promotes apoptosis and suppresses tumorigenicity by targeting Bcl-2. Oncol Rep. 2010;24(5):1363–9.
130. Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, et al. Role of miR-143 targeting KRAS in colorectal tumorigenesis. Oncogene. 2009;28(10):1385–92.
131. Wu G-S, Song Y-L, Yin Z-Q, Guo J-J, Wang S-P, Zhao W-W, et al. Ganoderiol A-enriched extract suppresses migration and adhesion of MDA-MB-231 cells by inhibiting FAK-SRC-paxillin cascade pathway. PLoS One. 2013;8(10):e76620.
132. Liu Z, Lu C-L, Cui L-P, Hu Y-L, Yu Q, Jiang Y, et al. MicroRNA-146a modulates TGF-β1-induced phenotypic differentiation in human dermal fibroblasts by targeting SMAD4. Arch Dermatol Res. 2012;304(3):195–202.
133. Geraldo M, Yamashita A, Kimura E. MicroRNA miR-146b-5p regulates signal transduction of TGF-β by repressing SMAD4 in thyroid cancer. Oncogene. 2011;31(15):1910–22.
134. Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL, et al. MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res. 2010;70(12):5184–93.
135. Ueno K, Hirata H, Shahryari V, Deng G, Tanaka Y, Tabatabai Z, et al. microRNA-183 is an oncogene targeting Dkk-3 and SMAD4 in prostate cancer. Br J Cancer. 2013;108(8):1659–67.
136. Mishra S, Deng J, Gowda P, Rao M, Lin C, Chen C, et al. Androgen receptor and microRNA-21 axis downregulates transforming growth factor beta receptor II (TGFBR2) expression in prostate cancer. Oncogene. 2014;33(31):4097–106.
137. Xu B, Niu X, Zhang X, Tao J, Wu D, Wang Z, et al. miR-143 decreases prostate cancer cells proliferation and migration and enhances their sensitivity to docetaxel through suppression of KRAS. Mol Cell Biochem. 2011;350(1-2):207–13.
138. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase—AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489–501.
139. Luo J, Manning BD, Cantley LC. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell. 2003;4(4):257–62.
140. Sun D, Lee YS, Malhotra A, Kim HK, Matecic M, Evans C, et al. miR-99 family of MicroRNAs suppresses the expression of prostate-specific antigen and prostate cancer cell proliferation. Cancer Res. 2011;71(4):1313–24.
141. Saini S, Majid S, Shahryari V, Arora S, Yamamura S, Chang I, et al. miRNA-708 control of CD44+ prostate cancer–initiating cells. Cancer Res. 2012;72(14):3618–30.
142. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010;18(1):11–22.
143. Rasheed SAK, Teo CR, Beillard EJ, Voorhoeve PM, Casey PJ. MicroRNA-182 and microRNA-200a control G-protein subunit α-13 (GNA13) expression and cell invasion synergistically in prostate cancer cells. J Biol Chem. 2013;288(11):7986–95.
144. LeRoy G, Loyola A, Lane WS, Reinberg D. Purification and characterization of a human factor that assembles and remodels chromatin. J Biol Chem. 2000;275(20):14787–90.
145. Gregory PA, Bracken CP, Bert AG, Goodall GJ. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle. 2008;7(20):3112–7.
146. Xu J, Lamouille S, Derynck R. TGF-β-induced epithelial to mesenchymal transition. Cell Res. 2009;19(2):156–72.
147. Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Investig. 2009;119(6):1420.
148. Comijn J, Berx G, Vermassen P, Verschueren K, van Grunsven L, Bruyneel E, et al. The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion. Mol Cell. 2001;7(6):1267–78.
149. Gonzales JC, Fink LM, Goodman Jr OB, Symanowski JT, Vogelzang NJ, Ward DC. Comparison of circulating MicroRNA 141 to circulating tumor cells, lactate dehydrogenase, and prostate-specific antigen for determining treatment response in patients with metastatic prostate cancer. Clin Genitourin Cancer. 2011;9(1):39–45.
150. Li Y, VandenBoom TG, Kong D, Wang Z, Ali S, Philip PA, et al. Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009;69(16):6704–12.
151. Takeshita F, Patrawala L, Osaki M, Takahashi R-U, Yamamoto Y, Kosaka N, et al. Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther. 2010;18(1):181–7.
152. Cole MD, Cowling VH. Transcription-independent functions of MYC: regulation of translation and DNA replication. Nat Rev Mol Cell Biol. 2008;9(10):810–5.
153. Griffith TS, Chin WA, Jackson GC, Lynch DH, Kubin MZ. Intracellular regulation of TRAIL-induced apoptosis in human melanoma cells. J Immunol. 1998;161(6):2833–40.
154. Zaman MS, Chen Y, Deng G, Shahryari V, Suh S, Saini S, et al. The functional significance of microRNA-145 in prostate cancer. Br J Cancer. 2010;103(2):256–64.
155. Liu C, Kelnar K, Vlassov AV, Brown D, Wang J, Tang DG. Distinct microRNA expression profiles in prostate cancer stem/progenitor cells and tumor-suppressive functions of let-7. Cancer Res. 2012;72(13):3393–404.
156. Majid S, Dar AA, Saini S, Shahryari V, Arora S, Zaman MS, et al. miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways. Clin Cancer Res. 2013;19(1):73–84.
157. Li L-C. AB74. MicroRNAs fuels cancer growth through the RNAa mechanism. Transl Androl Urol. 2014;3(S1). doi:10.3978/j.issn.2223-4683.2014.s074.
158. Seidegård J, Ekström G. The role of human glutathione transferases and epoxide hydrolases in the metabolism of xenobiotics. Environ Health Perspect. 1997;105 Suppl 4:791.
159. Singh S, Shukla GC, Gupta S. MicroRNA regulating glutathione S-transferase P1 in prostate cancer. Curr Pharmacol Rep. 2015;1(2):79–88.
160. Tao J, Wu D, Xu B, Qian W, Li P, Lu Q, et al. microRNA-133 inhibits cell proliferation, migration and invasion in prostate cancer cells by targeting the epidermal growth factor receptor. Oncol Rep. 2012;27(6):1967.
161. Uchida Y, Chiyomaru T, Enokida H, Kawakami K, Tatarano S, Kawahara K, et al., editors. MiR-133a induces apoptosis through direct regulation of GSTP1 in bladder cancer cell lines. Urol Oncol: Semin Ori. 2013;13(1):115–23.
162. Negi A, Gill B. Success stories of enolate form of drugs. PharmaTutor. 2013;1(2):45–53.
163. Petersen M, Nielsen CB, Nielsen KE, Jensen GA, Bondensgaard K, Singh SK, et al. The conformations of locked nucleic acids (LNA). J Mol Recognit. 2000;13(1):44–53.
164. Wiggins JF, Ruffino L, Kelnar K, Omotola M, Patrawala L, Brown D, et al. Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34. Cancer Res. 2010;70(14):5923–30.
165. Ji Q, Hao X, Zhang M, Tang W, Yang M, Li L, et al. MicroRNA miR-34 inhibits human pancreatic cancer tumor-initiating cells. PLoS One. 2009;4(8):e6816.
166. Bouchie A. First microRNA mimic enters clinic. Nat Biotechnol. 2013;31(7):577.
167. Zhang W, Winder T, Ning Y, Pohl A, Yang D, Kahn M, et al. A let-7 microRNA-binding site polymorphism in 3′-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol. 2011;22(1):104–9.
168. van Rooij E, Sutherland LB, Qi X, Richardson JA, Hill J, Olson EN. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science. 2007;316(5824):575–9.
169. Nana‐Sinkam S, Croce C. Clinical applications for microRNAs in cancer. Clin Pharmacol Ther. 2013;93(1):98–104.
170. Saini S, Majid S, Shahryari V, Tabatabai ZL, Arora S, Yamamura S, et al. Regulation of SRC kinases by microRNA-3607 located in a frequently deleted locus in prostate cancer. Mol Cancer Ther. 2014;13(7):1952–63.
171. Kogo R, Mimori K, Tanaka F, Komune S, Mori M. Clinical significance of miR-146a in gastric cancer cases. Clin Cancer Res. 2011;17(13):4277–84.
172. Hennessy EJ, Moore KJ. Using microRNA as an alternative treatment for hyperlipidemia and cardiovascular disease: cardio-miRs in the pipeline. J Cardiovasc Pharmacol. 2013;62(3):247.
173. Tomimaru Y, Eguchi H, Nagano H, Wada H, Kobayashi S, Marubashi S, et al. Circulating microRNA-21 as a novel biomarker for hepatocellular carcinoma. J Hepatol. 2012;56(1):167–75.
174. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S, et al. Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. J Clin Invest. 2011;121(7):2921.
175. Negi A, Gill B, Anand S. Tilling: versatile reverse genetic tool. PharmaTutor. 2014;2(1):26–32.
176. Taneja SS. A multidisciplinary approach to the management of hormone-refractory prostate cancer. Rev Urol. 2003;5 Suppl 2:S53.
177. Knudsen KE, Scher HI. Starving the addiction: new opportunities for durable suppression of AR signaling in prostate cancer. Clin Cancer Res. 2009;15(15):4792–8.
178. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat Rev Cancer. 2001;1(1):34–45.
179. Zhang S, Chen L, Jung EJ, Calin GA. Targeting microRNAs with small molecules: between dream and reality. Clin Pharmacol Ther. 2010;87(6):754.
180. Yang M, Mattes J. Discovery, biology and therapeutic potential of RNA interference, microRNA and antagomirs. Pharmacol Ther. 2008;117(1):94–104.
181. Ebert MS, Neilson JR, Sharp PA. MicroRNA sponges: competitive inhibitors of small RNAs in mammalian cells. Nat Methods. 2007;4(9):721–6.
182. Krützfeldt J, Kuwajima S, Braich R, Rajeev KG, Pena J, Tuschl T, et al. Specificity, duplex degradation and subcellular localization of antagomirs. Nucleic Acids Res. 2007;35(9):2885–92.
183. Cortez MA, Valdecanas D, Zhang X, Zhan Y, Bhardwaj V, Calin GA, et al. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther. 2014;22(8):1494–503.
184. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, Li H, et al. The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med. 2011;17(2):211–5.
185. Korpela E, Vesprini D, Liu S. MicroRNA in radiotherapy: miRage or miRador&quest. Br J Cancer. 2015;112:777–82.
186. Bentzen SM, Parliament M, Deasy JO, Dicker A, Curran WJ, Williams JP, et al. Biomarkers and surrogate endpoints for normal-tissue effects of radiation therapy: the importance of dose–volume effects. Int J Radiat Oncol Biol Phys. 2010;76(3):S145–50.
187. Hamama S, Noman MZ, Gervaz P, Delanian S, Vozenin M-C. MiR-210: a potential therapeutic target against radiation-induced enteropathy. Radiother Oncol. 2014;111(2):219–21.
188. Pan Y, Zhang Y, Jia T, Zhang K, Li J, Wang L. Development of a microRNA delivery system based on bacteriophage MS2 virus‐like particles. FEBS J. 2012;279(7):1198–208.
189. Zhang X, Zhu S, Li Z, Yuan X, Cui Z, Yang X, et al. Multilayer modification on titanium surface for in situ delivery of MicroRNAs. Mater Lett. 2014;133:243–6.
190. Izzard L, Ye S, Jenkins K, Xia Y, Tizard M, Stambas J. miRNA modulation of SOCS1 using an influenza A virus delivery system. J Gen Virol. 2014;95(Pt 9):1880–5.
191. Maier MA, Jayaraman M, Matsuda S, Liu J, Barros S, Querbes W, et al. Biodegradable lipids enabling rapidly eliminated lipid nanoparticles for systemic delivery of RNAi therapeutics. Mol Ther. 2013;21(8):1570–8.
192. Shi S, Han L, Deng L, Zhang Y, Shen H, Gong T, et al. Dual drugs (microRNA-34a and paclitaxel)-loaded functional solid lipid nanoparticles for synergistic cancer cell suppression. J Control Release. 2014;194:228–37.
193. Lin S-Y, Zhao W-Y, Tsai H-C, Hsu W-H, Lo C-L, Hsiue G-H. Sterically polymer-based liposomal complexes with dual-shell structure for enhancing the siRNA delivery. Biomacromolecules. 2012;13(3):664–75.
194. Wong SC, Klein JJ, Hamilton HL, Chu Q, Frey CL, Trubetskoy VS, et al. Co-injection of a targeted, reversibly masked endosomolytic polymer dramatically improves the efficacy of cholesterol-conjugated small interfering RNAs in vivo. Nucleic Acid Ther. 2012;22(6):380–90.
195. Hao Z, Fan W, Hao J, Wu X, Zeng GQ, Zhang LJ et al. Efficient delivery of micro RNA to bone-metastatic prostate tumors by using aptamer-conjugated atelocollagen in vitro and in vivo. Drug Deliv. 2014. p. 1-8.
196. Peltier HJ, Latham GJ. Normalization of microRNA expression levels in quantitative RT-PCR assays: identification of suitable reference RNA targets in normal and cancerous human solid tissues. RNA. 2008;14(5):844–52.